Dynamic change in the NS3 protease domain in HIV/HCV-coinfected patients naive to anti-HCV protease inhibitors

被引：0

作者：

Bagaglio, Sabrina ^{[1
,2
]}

Messina, Emanuela ^{[1
]}

Hasson, Hamid ^{[1
]}

Merli, Marco ^{[1
]}

Andolina, Andrea ^{[1
]}

Lazzarin, Adriano ^{[1
,2
]}

Uberti-Foppa, Caterina ^{[1
]}

Morsica, Giulia ^{[1
]}

机构：

[1] Osped San Raffaele, Dept Infect Dis, Milan, Italy

[2] Univ Vita Salute San Raffaele, Milan, Italy

来源：

NEW MICROBIOLOGICA | 2017年 / 40卷 / 01期

关键词：

NS3 protease inhibitors; HIV/HCV coinfection; RAS; HEPATITIS-C VIRUS; NATURAL-RESISTANCE; POLYMORPHISM; THERAPY; 1A;

D O I：

暂无

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

The genetic analysis of THE natural protease inhibitors (PI) resistance of HCV genotype (GT) 1 involves subtypes 1a and 1b. NS3 protease domain was sequentially analysed in 10 HIV/HCV GT1-coinfected individuals naive to HCV treatment. Analysis at different time points showed that 2/3 GT1b patients were infected by a GT1a clade1 during follow-up. In one patient a switch from clade1 to clade2 and in one other patient a switch from clade2 to clade1 was revealed. Four out of ten patients had resistance-associated substitutions (RASs) at baseline. The dynamics of the dominant infecting subtype suggests the presence of mixed infection in some patients.

引用

页码：53 / 55

页数：3

共 50 条

[1] Hepatitis C virus (HCV) protease variability and anti-HCV protease inhibitor resistance in HIV/HCV-coinfected patients
Trimoulet, P.
Belzunce, C.
Faure, M.
Wittkop, L.
Reigadas, S.
Dupon, M.
Ragnaud, J-M
Fleury, H.
Neau, D.
HIV MEDICINE, 2011, 12 (08) : 506 - 509
[2] Macrocyclic inhibitors of HCV NS3 protease
Venkatraman, Srikanth
Njoroge, F. George
EXPERT OPINION ON THERAPEUTIC PATENTS, 2009, 19 (09) : 1277 - 1303
[3] Evaluating Drug Resistant Mutations to HCV NS3 Protease Inhibitors in Iranian Naive Patients
Hashempour, Tayebeh
Dehghani, Behzad
Mousavi, Zahra
Yahaghi, Maryam
Hasanshahi, Zahra
Moayedi, Javad
Akbari, Tahereh
Davarpanah, Mohammad Ali
INTERNATIONAL JOURNAL OF PEPTIDE RESEARCH AND THERAPEUTICS, 2020, 26 (04) : 1699 - 1710
[4] Resistance to anti-HCV protease inhibitors
Thompson, Alexander J.
Locarnini, Stephen A.
Beard, Michael R.
CURRENT OPINION IN VIROLOGY, 2011, 1 (06) : 599 - 606
[5] Discovering novel anti-HCV compounds with inhibitory activities toward HCV NS3/4A protease
Yu, Ye
Jing, Jing-feng
Tong, Xian-kun
He, Pei-lan
Li, Yuan-chao
Hu, You-hong
Tang, Wei
Zuo, Jian-ping
ACTA PHARMACOLOGICA SINICA, 2014, 35 (08) : 1074 - 1081
[6] Discovering novel anti-HCV compounds with inhibitory activities toward HCV NS3/4A protease
Ye Yu
Jing-feng Jing
Xian-kun Tong
Pei-lan He
Yuan-chao Li
You-hong Hu
Wei Tang
Jian-ping Zuo
Acta Pharmacologica Sinica, 2014, 35 : 1074 - 1081
[7] Boceprevir, an NS3 Protease Inhibitor of HCV
Berman, Kenneth
Kwo, Paul Y.
CLINICS IN LIVER DISEASE, 2009, 13 (03) : 429 - +
[8] Use of first-generation HCV protease inhibitors in patients coinfected by HIV and HCV genotype 1
Salmon-Ceron, Dominique
Arvieux, Cedric
Bourliere, Marc
Cacoub, Patrice
Halfon, Philippe
Lacombe, Karine
Pageaux, Georges-Philippe
Pialoux, Gilles
Piroth, Lionel
Poizot-Martin, Isabelle
Rosenthal, Eric
Pol, Stanislas
LIVER INTERNATIONAL, 2014, 34 (06) : 869 - 889
[9] Characterization of HCV NS3 Protease Variants in HCV/ HIV-Coinfected Patients by Ultra-Deep Sequence Analysis: Relationship with Hepatic Fibrosis
Abdel-hameed, Enass A.
Rouster, Susan D.
Zhang, Xiang
Chen, Jing
Medvedovic, Mario
Goodman, Zachary D.
Sherman, Kenneth E.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2017, 74 (03) : 353 - 358
[10] HCV NS3 naturally occurring variants in HIV/HCV coinfected DAA-naive patients: consideration for HCV genotyping resistance testing
Ruggiero, T.
Burdino, E.
Calcagno, A.
Bonora, S.
Boglione, L.
Di Perri, G.
Ghisetti, V.
INFECTION, 2016, 44 (06) : 789 - 792

← 1 2 3 4 5 →